You are here

Pivotal Phase 3 Studies Planned for Treatment of <i>Clostridium Difficile</i>-Associated Diarrhea

The studies are designed to compare the end-of-therapy response rates with CB-315 and oral vancomycin and to evaluate the safety of CB-315 in patients with CDAD. In addition, investigators will look at sustained clinical response after treatment.

CDAD is a disease caused by an overgrowth of, and subsequent toxin production by, C. difficile, a resident anaerobic spore-forming Gram-positive bacterium of the lower gastrointestinal (GI) tract. The overgrowth of C. difficile in the GI tract is caused by the use of antibiotics for the treatment of common community and hospital-acquired infections. Although antibiotics treat the underlying infection, many of these drugs disrupt the natural gut flora and allow C. difficile to proliferate. C. difficile produces toxins that can lead to severe diarrhea, sepsis, and even death.

For more information, visit

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
Nexus Has Increased Power, RF Capabilities